Fibromyalgia Therapeutics: Market Research Report
This report analyzes the Global market for Fibromyalgia Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2015 through 2022.
Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research.
Company profiles are primarily based on public domain information including company URLs.
The report profiles 22 companies including many key and niche players such as -
Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research.
Company profiles are primarily based on public domain information including company URLs.
The report profiles 22 companies including many key and niche players such as -
- Allergan plc
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- Innovative Med Concepts, Inc.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Fibromyalgia Syndrome: A Prelude
Fibromyalgia Therapeutics Market: A Nascent Sector
A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio
FDA Approved Fibromyalgia Drugs
IMC-1: A Revolutionary Combination Therapy
Daiichi Sankyo’s Mirogabalin Drug Improvises on Lyrica
Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine
Understanding Heightened Effect of Pain in Women Due to Fibromyalgia
Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses
Fibromyalgia Treatment through High-Pressure Oxygen Application
EU approves New Device to Treat Fibromyalgia and Migraine
2. AVAILABLE & PIPELINE FIBROMYALGIA DRUGS – AN OVERVIEW
Medications Used in the Fibromyalgia Treatment
Pain Relievers
Antidepressants
Anti-Seizure Drugs
Medication for Improving Sleep
Muscle Relaxants
Antipsychotics
A Glance at Available Fibromyalgia Drugs
Lyrica (pregabalin)
Cymbalta (duloxetine HCl)
Savella (milnacipran HCl)
Fibromyalgia Products in Pipeline
Mirogabalin
IMC-1
SWT06101
3. FIBROMYALGIA – THE DISEASE, SYMPTOMS, AND DIAGNOSIS
4. MANAGEMENT OF FIBROMYALGIA
Non-Pharmacological Treatment of Fibromyalgia
Nutritional Therapy
Exercise
Cognitive Behavior Therapy
Pharmacological Treatment Alternatives for Fibromyalgia
Antidepressants
Tricyclic Antidepressants (TCA)
Dopamine Agonists
Muscle Relaxants
Selective Serotonin-Norephinephrine Inhibitors (SNRIs)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Drug Therapy for Fibromyalgia-Related Fatigue
Other Therapeutic Agents for Fibromyalgia Treatment
Conclusion
5. CLINICAL STUDIES & PRODUCT LAUNCHES/APPROVALS
Cannabis Science Introduces Fibromyalgia Pain Relief Medication
Soterix Medical Launches PainX tDCS Treatment in Canada
Synovation Medical Group to Conduct Study on NeuroMetrix’s Quell Wearable Pain Relief Technology
FDA Grants Fast Track Designation to Innovative Med Concepts’ IMC-1
Soterix Medical’s PainX Treatment Receives CE Mark Approval
Tonix Pharmaceuticals Begins Phase 3 Trial of TNX-102 SL
Pfizer’s Lyrica Fails to Meet FDA Requirements in Post-Marketing Study
Premier Biomedical to Submit Application to FDA for Fibromyalgia Therapy
6. FOCUS ON SELECT GLOBAL PLAYERS
Allergan plc (Ireland)
Boehringer Ingelheim GmbH (Germany)
Daiichi Sankyo Company Limited (Japan)
Eli Lilly and Company (USA)
Innovative Med Concepts, Inc. (USA)
Pfizer, Inc. (USA)
Pierre Fabre Médicament (France)
SWITCHBIOTECH LLC (USA)
Zynerba Pharmaceuticals, Inc. (USA)
7. GLOBAL MARKET PERSPECTIVE
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 22 (including Divisions/Subsidiaries - 23)
The United States (12)
Canada (1)
Japan (4)
Europe (5)
France (1)
Germany (1)
Rest of Europe (3)
Asia-Pacific (Excluding Japan) (1)
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Fibromyalgia Syndrome: A Prelude
Table 1. Prevalence Rate (%) of Fibromyalgia Condition in Select Countries (includes corresponding Graph/Chart)
Table 2. Prevalence Rate (%) of Fibromyalgia among Women by Age Group (includes corresponding Graph/Chart)
Fibromyalgia Therapeutics Market: A Nascent Sector
A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio
FDA Approved Fibromyalgia Drugs
IMC-1: A Revolutionary Combination Therapy
Daiichi Sankyo’s Mirogabalin Drug Improvises on Lyrica
Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine
Understanding Heightened Effect of Pain in Women Due to Fibromyalgia
Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses
Fibromyalgia Treatment through High-Pressure Oxygen Application
EU approves New Device to Treat Fibromyalgia and Migraine
2. AVAILABLE & PIPELINE FIBROMYALGIA DRUGS – AN OVERVIEW
Medications Used in the Fibromyalgia Treatment
Pain Relievers
Antidepressants
Anti-Seizure Drugs
Medication for Improving Sleep
Muscle Relaxants
Antipsychotics
A Glance at Available Fibromyalgia Drugs
Lyrica (pregabalin)
Cymbalta (duloxetine HCl)
Savella (milnacipran HCl)
Fibromyalgia Products in Pipeline
Mirogabalin
IMC-1
SWT06101
3. FIBROMYALGIA – THE DISEASE, SYMPTOMS, AND DIAGNOSIS
4. MANAGEMENT OF FIBROMYALGIA
Non-Pharmacological Treatment of Fibromyalgia
Nutritional Therapy
Exercise
Cognitive Behavior Therapy
Pharmacological Treatment Alternatives for Fibromyalgia
Antidepressants
Tricyclic Antidepressants (TCA)
Dopamine Agonists
Muscle Relaxants
Selective Serotonin-Norephinephrine Inhibitors (SNRIs)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Drug Therapy for Fibromyalgia-Related Fatigue
Other Therapeutic Agents for Fibromyalgia Treatment
Conclusion
5. CLINICAL STUDIES & PRODUCT LAUNCHES/APPROVALS
Cannabis Science Introduces Fibromyalgia Pain Relief Medication
Soterix Medical Launches PainX tDCS Treatment in Canada
Synovation Medical Group to Conduct Study on NeuroMetrix’s Quell Wearable Pain Relief Technology
FDA Grants Fast Track Designation to Innovative Med Concepts’ IMC-1
Soterix Medical’s PainX Treatment Receives CE Mark Approval
Tonix Pharmaceuticals Begins Phase 3 Trial of TNX-102 SL
Pfizer’s Lyrica Fails to Meet FDA Requirements in Post-Marketing Study
Premier Biomedical to Submit Application to FDA for Fibromyalgia Therapy
6. FOCUS ON SELECT GLOBAL PLAYERS
Allergan plc (Ireland)
Boehringer Ingelheim GmbH (Germany)
Daiichi Sankyo Company Limited (Japan)
Eli Lilly and Company (USA)
Innovative Med Concepts, Inc. (USA)
Pfizer, Inc. (USA)
Pierre Fabre Médicament (France)
SWITCHBIOTECH LLC (USA)
Zynerba Pharmaceuticals, Inc. (USA)
7. GLOBAL MARKET PERSPECTIVE
Table 3. World Recent Past, Current and Future Analysis for Fibromyalgia Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 4. World Historic Review for Fibromyalgia Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 5. World 14-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)
Table 6. European Recent Past, Current and Future Analysis for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 7. European Historic Review for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 8. European 14-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 22 (including Divisions/Subsidiaries - 23)
The United States (12)
Canada (1)
Japan (4)
Europe (5)
France (1)
Germany (1)
Rest of Europe (3)
Asia-Pacific (Excluding Japan) (1)
